BioAscent has been recognised for its exceptional performance in 2021. Specifically, BioAscent was congratulated for achieving incredible growth, with business doubling and headcount tripling in the past couple of years.
BioAscent’s recognition comes as part of the British Private Equity and Venture Capital Association’s (BVCA) ‘Vision 2022’ initiative. Vision 2022, produced in collaboration with Grant Thornton, shines a light on the best management teams backed by the BVCA’s private equity and venture capital members.
Let's talk about how we can maximise your drug discovery success.